<DOC>
	<DOC>NCT00499993</DOC>
	<brief_summary>The purpose of the protocol, is to evaluate if lanreotide Autogel 120 mg is effective in the control of Growth Hormone (GH) secretion in patients with active acromegaly.</brief_summary>
	<brief_title>Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Documented diagnosis of active acromegaly, defined by serum GH levels above 5 µg/L, absence of reduction of serum GH levels below 1µg/L after oral glucose tolerance test (OGTT) and abnormal IGF1 values Patients who have undergone pituitary surgery less than 3 months before selection Patients previously treated with radiotherapy Patients previously treated with somatostatin analogue except for a presurgical treatment not longer than 3 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>